Trade Mind Medicine (MindMed) Inc. Subordinate Voting Shares - MNMD CFD

Add to favourite

8.69

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.07

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.01

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Mind Medicine (MindMed) Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	8.87
Open*	9.45
1-Year Change*	173.12%
Day's Range*	8.86 - 9.45
52 wk Range	2.41-5.01
Average Volume (10 days)	715.00K
Average Volume (3 months)	11.80M
Market Cap	145.54M
P/E Ratio	-100.00K
Shares Outstanding	40.09M
Revenue	N/A
EPS	-1.99
Dividend (Yield %)	N/A
Beta	-7.16
Next Earnings Date	Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	8.87	-0.64	-6.73%	9.51	9.56	8.84
Apr 17, 2024	9.51	-0.38	-3.84%	9.89	9.98	9.47
Apr 16, 2024	9.87	0.30	3.13%	9.57	9.99	9.27
Apr 15, 2024	9.77	-0.07	-0.71%	9.84	10.38	9.59
Apr 12, 2024	9.64	-0.50	-4.93%	10.14	10.37	9.49
Apr 11, 2024	10.20	-0.52	-4.85%	10.72	10.84	9.92
Apr 10, 2024	10.86	1.20	12.42%	9.66	10.97	9.49
Apr 9, 2024	10.04	-0.80	-7.38%	10.84	10.88	9.92
Apr 8, 2024	10.85	-0.13	-1.18%	10.98	11.33	10.74
Apr 5, 2024	10.98	0.11	1.01%	10.87	11.13	10.62
Apr 4, 2024	10.76	-1.25	-10.41%	12.01	12.07	10.60
Apr 3, 2024	11.69	2.12	22.15%	9.57	12.12	9.57
Apr 2, 2024	9.82	0.61	6.62%	9.21	9.85	8.95
Apr 1, 2024	9.48	0.21	2.27%	9.27	9.56	9.00
Mar 28, 2024	9.35	-0.04	-0.43%	9.39	9.97	9.22
Mar 27, 2024	9.47	-0.43	-4.34%	9.90	9.98	9.32
Mar 26, 2024	9.83	-0.61	-5.84%	10.44	10.78	9.78
Mar 25, 2024	10.42	0.69	7.09%	9.73	10.76	9.31
Mar 22, 2024	9.72	0.00	0.00%	9.72	10.67	9.59
Mar 21, 2024	9.71	-0.19	-1.92%	9.90	10.39	9.65

Mind Medicine (MindMed) Inc. Subordinate Voting Shares Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 10:59	Country CA	Event Q1 2024 Mind Medicine (MindMed) Inc Earnings Release Q1 2024 Mind Medicine (MindMed) Inc Earnings Release Forecast - Previous -
Thursday, June 20, 2024
Time (UTC) 14:00	Country CA	Event Mind Medicine (MindMed) Inc Annual Shareholders Meeting Mind Medicine (MindMed) Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 10:59	Country CA	Event Q2 2024 Mind Medicine (MindMed) Inc Earnings Release Q2 2024 Mind Medicine (MindMed) Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2019
Total revenue	0	0	0	0	0
Total Operating Expense	66.331	93.854	33.03	1.10593	5.42921
Selling/General/Admin. Expenses, Total	30.162	59.065	14.399	0.457414	3.10517
Research & Development	32.969	34.789	18.631		2.04904
Depreciation / Amortization	3.2			0.006625	0.275
Interest Expense (Income) - Net Operating
Operating Income	-66.331	-93.854	-33.03	-1.10593	-5.42921
Interest Income (Expense), Net Non-Operating	1.69	-0.445	-0.907	0	0.02751
Other, Net	7.845	0.106	0		-0.0725
Net Income Before Taxes	-56.796	-94.193	-33.937	-1.10593	-5.47421
Net Income After Taxes	-56.796	-93.036	-33.937	-1.10593	-5.47421
Net Income Before Extra. Items	-56.796	-93.036	-33.937	-1.10593	-5.47421
Net Income	-56.796	-93.036	-33.937	-1.10593	-5.47421
Income Available to Common Excl. Extra. Items	-56.796	-93.036	-33.937	-1.10593	-5.47421
Income Available to Common Incl. Extra. Items	-56.796	-93.036	-33.937	-1.10593	-5.47421
Diluted Net Income	-56.796	-93.036	-33.937	-1.10593	-5.47421
Diluted Weighted Average Shares	30.8575	27.3785	17.7489	0.37943	6.92954
Diluted EPS Excluding Extraordinary Items	-1.84059	-3.39815	-1.91206	-2.91472	-0.78998
Diluted Normalized EPS	-1.84059	-3.39815	-1.91206	-1.22299	-0.78998
Unusual Expense (Income)				0.64189

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0	0	0
Total Operating Expense	29.184	20.862	13.9	16.983	16.943
Selling/General/Admin. Expenses, Total	14.407	8.263	5.07	9.211	7.617
Research & Development	13.977	11.799	8.03	6.972	8.526
Operating Income	-29.184	-20.862	-13.9	-16.983	-16.943
Interest Income (Expense), Net Non-Operating	1.558	1.232	1.153	0.498	-0.007
Other, Net	-1.504	-5.185	7.844	0	-0.007
Net Income Before Taxes	-29.13	-24.815	-4.903	-16.485	-16.957
Net Income After Taxes	-29.13	-24.815	-4.903	-16.485	-16.957
Net Income Before Extra. Items	-29.13	-24.815	-4.903	-16.485	-16.957
Net Income	-29.13	-24.815	-4.903	-16.485	-16.957
Income Available to Common Excl. Extra. Items	-29.13	-24.815	-4.903	-16.485	-16.957
Income Available to Common Incl. Extra. Items	-29.13	-24.815	-4.903	-16.485	-16.957
Diluted Net Income	-29.13	-24.815	-4.903	-16.485	-16.957
Diluted Weighted Average Shares	38.5764	38.0773	37.7314	29.2963	28.2434
Diluted EPS Excluding Extraordinary Items	-0.75513	-0.6517	-0.12994	-0.5627	-0.60039
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.75513	-0.6517	-0.12994	-0.5627	-0.60039
Depreciation / Amortization	0.8	0.8	0.8	0.8	0.8
Unusual Expense (Income)

Annual
Quarterly

	2022	2021	2020	2019	2019
Total Current Assets	146.055	137.215	81.519	2.84093	6.73654
Cash and Short Term Investments	142.142	133.539	80.094	0.017347	3.01645
Cash & Equivalents				0.017347
Short Term Investments
Total Receivables, Net				0.004914
Prepaid Expenses	3.913	3.676	1.425	0.020812	0.0342
Total Assets	169.993	164.002	81.519	2.84093	11.9615
Property/Plant/Equipment, Total - Net				0
Other Long Term Assets, Total	0.331			0
Total Current Liabilities	17.892	10.408	3.008	0.139958	1.9612
Accounts Payable	2.111	4.178	2.022	0.139958	1.9612
Notes Payable/Short Term Debt	0	0	0	0	0
Total Liabilities	19.076	12.338	5.651	0.192458	1.9612
Total Long Term Debt	0	0	0	0	0
Total Equity	150.917	151.664	75.868	2.64847	10.0003
Common Stock	0	0		5.37358	15.3218
Additional Paid-In Capital	344.758	288.29	120.22	0.772294
Retained Earnings (Accumulated Deficit)	-194.468	-137.672	-44.636	-3.53096	-5.32143
Other Equity, Total	0.627	1.046	0.284	0.033559
Total Liabilities & Shareholders’ Equity	169.993	164.002	81.519	2.84093	11.9615
Total Common Shares Outstanding	37.9791	28.1022	20.96	0.40552	11.0999
Other Liabilities, Total	1.184	1.93	2.643	0.052501	0
Other Current Assets, Total				2.79786	3.6859
Cash	142.142	133.539	80.094		3.01645
Intangibles, Net	3.689	6.869	0		5.225
Goodwill, Net	19.918	19.918	0
Accrued Expenses	5.877	6.23	0.986
Other Current Liabilities, Total	9.904

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	120.086	119.791	132.413	146.055	156.51
Cash and Short Term Investments	117.699	116.895	129.409	142.142	154.519
Cash	117.699	116.895	129.409	142.142	154.519
Prepaid Expenses	2.387	2.896	3.004	3.913	1.826
Other Current Assets, Total					0.165
Total Assets	141.55	142.085	155.529	169.993	180.907
Property/Plant/Equipment, Total - Net
Goodwill, Net	19.918	19.918	19.918	19.918	19.918
Intangibles, Net	1.317	2.108	2.898	3.689	4.479
Total Current Liabilities	31.154	35.121	24.096	17.892	26.038
Accounts Payable	7.686	8.577	2.32	2.111	0.824
Notes Payable/Short Term Debt	0	0	0	0	0
Total Liabilities	45.571	36.113	25.185	19.076	27.314
Total Long Term Debt	14.068	0	0	0	0
Deferred Income Tax
Total Equity	95.979	105.972	130.344	150.917	153.593
Common Stock	0	0	0	0	0
Additional Paid-In Capital	361.538	354.023	348.986	344.758	342.415
Retained Earnings (Accumulated Deficit)	-266.336	-248.413	-219.283	-194.468	-189.565
Other Equity, Total	0.777	0.362	0.641	0.627	0.743
Total Liabilities & Shareholders’ Equity	141.55	142.085	155.529	169.993	180.907
Total Common Shares Outstanding	40.0947	38.8072	38.2901	37.9791	37.5411
Accrued Expenses	9.957	9.95	6.687	5.877	7.467
Other Liabilities, Total	0.349	0.992	1.089	1.184	1.276
Other Current Liabilities, Total	13.511	16.594	15.089	9.904	17.747
Other Long Term Assets, Total	0.229	0.268	0.3	0.331
Long Term Debt	14.068

Annual
Quarterly

	2022	2021	2020	2019	2019
Net income/Starting Line	-56.796	-93.036	-33.937	-1.10477	-5.47421
Cash From Operating Activities	-50.139	-45.824	-23.597	-0.206066	-3.19971
Cash From Operating Activities				0.006618
Non-Cash Items	7.079	42.716	8.279	0.686323	0.0725
Changes in Working Capital	-3.602	3.037	2.061	0.205774	1.927
Cash From Investing Activities	0	-0.297	0	-0.211048
Capital Expenditures				-0.310361
Other Investing Cash Flow Items, Total	0	-0.297	0	0.099313
Cash From Financing Activities	59.051	98.824	96.704	0.285516	9.90205
Issuance (Retirement) of Stock, Net	59.458	98.824	97.099	0.285516	9.90205
Issuance (Retirement) of Debt, Net				0
Foreign Exchange Effects	-0.309	0.742	0.284	-0.001382
Net Change in Cash	8.603	53.445	73.391	-0.132972	6.70234
Amortization	3.18	2.616	0		0.275
Deferred Taxes	0	-1.157	0
Financing Cash Flow Items	-0.407	0	-0.395

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-24.815	-56.796	-51.893	-35.408	-18.451
Cash From Operating Activities	-13.331	-50.139	-37.29	-27.993	-12.866
Amortization	0.791	3.18	2.39	1.6	0.78
Non-Cash Items	8.967	7.079	13.861	8.062	3.792
Changes in Working Capital	1.726	-3.602	-1.648	-2.247	1.013
Cash From Investing Activities		0	0	0	0
Other Investing Cash Flow Items, Total		0	0	0	0
Cash From Financing Activities	0.583	59.051	58.635	0.424	-0.166
Financing Cash Flow Items	0	-0.407	-0.407	-0.407	-0.407
Issuance (Retirement) of Stock, Net	0.583	59.458	59.042	0.831	0.241
Foreign Exchange Effects	0.015	-0.309	-0.365	-0.229	-0.035
Net Change in Cash	-12.733	8.603	20.98	-27.798	-13.067
Capital Expenditures
Deferred Taxes		0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Mind Medicine (MindMed) Company profile

Mind Medicine (MindMed) Inc is a biopharmaceutical company that develops clinical-stage psychedelic medicines to treat brain health disorders. The New York-based firm specialises in psychiatry, addiction, pain management and neurology.

Founded in May 2019, MindMed has several drug candidates targeting serotonin, dopamine and acetylcholine systems. These products are based on psychedelic and empathogen substances. The company’s main drug candidate is MM-120, which is a proprietary, pharmaceutically optimised form of LSD. The medication is being developed to treat generalised anxiety disorder (GAD). MindMed is also researching the drug in various dosing regimens for the treatment of attention deficit hyperactivity disorder, also known as attention-deficit/hyperactivity disorder (ADHD), as well as chronic pain.

MM-110, the company’s second advanced drug, is being developed to treat opioid withdrawal. The MM-110, also known by the non-proprietary name zolunicant, is a form of 18-methoxycoronaridine, an ibogaine congener.

The company’s third medicine candidate is MM-402, or R(-)-MDMA, a proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). The medicine is being developed for the treatment of core symptoms of autism spectrum disorder.

In addition to its advanced stage drugs, the company also has several earlier stage research programmes through external collaboration, including a multi-year exclusive partnership with University Hospital Basel (UHB) in Switzerland.

MindMed does not own or operate any manufacturing facilities. All clinical and non-clinical materials are supplied by third-party contract manufacturing organisations, or CMOs.

MindMed went public on 27 February 2020 on the Toronto-based NEO Exchange under the ticker ‘MMED’. It is listed on Nasdaq under the symbol ‘MNMD’ and in Germany under the ticker ‘BGHM’.

Industry:

Biotechnology & Medical Research (NEC)

One World Trade Center
Suite 8500
NEW YORK
NEW YORK 10007
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024